Edition:
India

Anthem Inc (ANTM.N)

ANTM.N on New York Stock Exchange

282.67USD
12 Nov 2018
Change (% chg)

$-4.39 (-1.53%)
Prev Close
$287.06
Open
$287.21
Day's High
$288.03
Day's Low
$282.27
Volume
177,486
Avg. Vol
319,243
52-wk High
$290.77
52-wk Low
$215.58

Chart for

About

Anthem, Inc. is a health benefits company. The Company operates through three segments: Commercial and Specialty Business, Government Business and Other. It offers a spectrum of network-based managed care plans to large and small employer, individual, Medicaid and Medicare markets. Its managed care plans include preferred... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $73,110.36
Shares Outstanding(Mil.): 258.64
Dividend: 0.75
Yield (%): 1.06

Financials

UPDATE 3-Anthem predicts better 2019 than Wall Street forecast, shares rise

Oct 31 Anthem Inc on Wednesday said its own expectations for 2019 earnings are ahead of current Wall Street estimates and the health insurer also raised its 2018 profit forecast, and its shares rose as much as 5 percent.

31 Oct 2018

Takeda hikes annual profit forecast by a third after second-quarter profit jump

TOKYO Japan's Takeda Pharmaceutical Co Ltd on Wednesday boosted its annual operating profit outlook by a third after second-quarter earnings surged on strong global sales of its drugs for bowel disease and multiple myeloma.

31 Oct 2018

CORRECTED-UPDATE 1-Anthem quarterly profit beats estimates, raises 2018 forecast

Oct 31 Anthem Inc reported quarterly profit that topped analysts' estimates on Wednesday on lower medical costs and the No.2 U.S. health insurer raised its full-year adjusted earnings forecast.

31 Oct 2018

UPDATE 2-Takeda hikes annual profit forecast by a third after Q2 profit jump

* Boosted by strong sales of bowel disease, multiple myeloma drugs (Adds executive comments from news conference)

31 Oct 2018

Anthem reports 28.5 pct rise in quarterly profit

Oct 31 Anthem Inc reported a 28.5 percent rise in quarterly profit on Wednesday, as the U.S. health insurer reined in medical costs.

31 Oct 2018

Takeda's raises full-year outlook after Q2 profit rise

TOKYO, Oct 31 Takeda Pharmaceutical Co Ltd on Wednesday raised its annual operating profit outlook to 268.9 billion yen.

31 Oct 2018

Deals of the day-Mergers and acquisitions

Oct 29 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

30 Oct 2018

Deals of the day-Mergers and acquisitions

Oct 29 The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Monday: ** IBM Corp said on Sunday it had agreed to acquire U.S. software company Red Hat Inc for $34 billion, including debt, as it seeks to diversify its technology hardware and consulting business into higher-margin products and services. ** Australian adult education provider Navitas Ltd rebuffed a A$1.97 billion ($1.4 billion) approach from its founder and a private equity firm, leaving s

29 Oct 2018

UPDATE 1-UK Stocks-Factors to watch on Oct 29

Oct 29 - Britain's FTSE 100 index is seen opening 10 points higher at 6,949 on Monday, according to financial bookmakers, with FTSE 100 futures up 0.87 percent ahead of the cash market open.

29 Oct 2018

Takeda proposes sale of Shire drug to gain European approval

Takeda Pharmaceutical Co Ltd has proposed to European regulators it could sell a Shire treatment in development due to concerns of overlap in inflammatory bowel disease treatments and its own drug Entyvio as it seeks clearance for the two companies' merger.

29 Oct 2018

Earnings vs. Estimates